Remicade Sales Data

Rank 8 Current sales rank, all
U.S. Pharmaceuticals.

Last updated: February 2014 (updated quarterly).
The following data shows Remicade U.S. retail sales in Q4 2013 compared to previous quarters.

Date Range Sales Rank Sales ($000) Units (000)
Q4 2013 8 -2.71% -4.85%
Q3 2013 8 2.60% 2.42%
Q2 2013 8 2.76% 1.19%
Q1 2013 8 3.58% 2.51%
Q4 2012 8 -1.73% -4.32%
Q3 2012 8 (2) 2.02% 1.76%
Q2 2012 10 (1) 3.76% 2.38%
Q1 2012 11 (2) 10.04% 10.04%
Q4 2011 13 (3) -7.02% -9.82%
Q3 2011 10 1.52% 1.03%
Q2 2011 10 (2) 7.61% 7.11%
Q1 2011 12

* Units refer to the number of packages sold.

Source: IMS Health (Midas). Please review our terms of use and attribution guidelines. Copyright - All rights reserved. Unauthorized use and/or duplication of this material without express written permission is strictly prohibited.

Related News

DateArticle
September 26, 2011Remicade Approved for Ulcerative Colitis in Children
August 23, 2011Injectable Psoriasis Drugs May Not Hike Heart Risks: Study
September 4, 2008FDA Demands Tougher Warnings on Immunosuppressive Drugs
June 4, 2008Amgen and Wyeth Statement on the FDA Early Communication About Tumor Necrosis Factor (TNF) Blockers
June 4, 2008Early Communication About an Ongoing Safety Review of Tumor Necrosis Factor (TNF) Blockers (marketed as Remicade, Enbrel, Humira, and Cimzia)
Hide
(web1)